Helicobacter pylori

Current Opinion in Gastroenterology

Volumn 30, Issue 6, 2014, Pages 589-595

  Malfertheiner, Peter ^a   Selgrad, Michael ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Eradication therapy; Extragastric malignancies; Helicobacter pylori; Prevention

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; PROBIOTIC AGENT; TETRACYCLINE; ANTIINFECTIVE AGENT; BISMUTH; PROTON PUMP INHIBITOR;

ANTIBIOTIC RESISTANCE; CANCER PREVENTION; DISEASE ERADICATION; DRUG EFFICACY; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; PRIMARY PREVENTION; REVIEW; RISK FACTOR; SECONDARY PREVENTION; STOMACH CANCER; TREATMENT DURATION; TREATMENT INDICATION; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; HELICOBACTER INFECTIONS; MICROBIOLOGY; STOMACH NEOPLASMS;

ANTI-BACTERIAL AGENTS; BISMUTH; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LEVOFLOXACIN; METRONIDAZOLE; PROTON PUMP INHIBITORS; STOMACH NEOPLASMS;

EID: 84921728783     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000128     Document Type: Review

References (55)

1. Ierardi E, Giorgio F, Losurdo G, et al. How antibiotic resistances could change Helicobacter pylori treatment: a matter of geography? World J Gastroenterol 2013;19:8168-8180.
2. Song M, Ang TL. Second and third line treatment options for Helicobacter pylori eradication. World J Gastroenterol 2014;20:1517-1528.
3. Marzio L, Cellini L, Amitrano M, et al. Helicobacter pylori isolates from proximal and distal stomach of patients never treated and already treated show genetic variability and discordant antibiotic resistance. Eur J Gastroenterol Hepatol 2011;23:467-472.
4. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007;26:343-357.
5. Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62:34-42. Multicenter study evaluating H. pylori resistance to antibiotics in 19 European countries.
6. Wolle K, Leodolter A, Malfertheiner P, Konig W. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol 2002;51:705-709.
7. Selgrad M, Meissle J, Bornschein J, et al. Antibiotic susceptibility of Helicobacter pylori in central Germany and its relationship with the number of eradication therapies. Eur J Gastroenterol Hepatol 2013;25:1257-1260.
8. Liang X, Xu X, Zheng Q, et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol 2013;11:802-807.
9. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-664.
10. Wueppenhorst N, Stueger HP, Kist M, Glocker EO. High secondary resistance to quinolones in German Helicobacter pylori clinical isolates. J Antimicrob Chemother 2013;68:1562-1566.
11. Oleastro M, Cabral J, Ramalho PM, et al. Primary antibiotic resistance of Helicobacter pylori strains isolated from Portuguese children: a prospective multicentre study over a 10 year period. J Antimicrob Chemother 2011;66:2308-2311.
12. Rao GA, Mann JR, Shoaibi A, et al. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med 2014;12:121-127.
13. Fuccio L, Minardi ME, Zagari RM, et al. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007;147:553-562.
14. Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013;12:CD008337. Cochrane analysis showing that prolongation of eradication therapy increases treatment success.
15. Liou JM, Chen CC, Chen MJ, et al. Sequential versus triple therapy for the firstline treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013;381:205-213. Multicenter prospective trial demonstrating superiority of sequential therapy compared with triple therapy.
16. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013;347:f4587.
17. Zhou L, Zhang J, Chen M, et al. A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial. Am J Gastroenterol 2014;109:535-541.
18. Yoon H, Lee DH, Kim N, et al. Meta-analysis: is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults? J Gastroenterol Hepatol 2013;28:1801-1809.
19. Chung JW, Ha M, Yun SC, et al. Meta-analysis: sequential therapy is superior to conventional therapy for Helicobacter pylori infection in Korea. Korean J Gastroenterol 2013;62:267-271.
20. McNicholl AG, Marin AC, Molina-Infante J, et al. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 2014;63:244-249.
21. Federico A, Nardone G, Gravina AG, et al. Efficacy of 5-day levofloxacincontaining concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterology 2012;143:55-61.
22. Liao J, Zheng Q, Liang X, et al. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter 2013;18:373-377.
23. Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, noninferiority, phase 3 trial. Lancet 2011;377:905-913.
24. Molina-Infante J, Romano M, Fernandez-Bermejo M, et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 2013;145:121-128.
25. De FV, Hassan C, Ridola L, et al. Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study. J Med Microbiol 2014;63:748-752.
26. Sardarian H, Fakheri H, Hosseini V, et al. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. Helicobacter 2013;18:129-134.
27. Lee JY, Kim N, Kim MS, et al. Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. Dig Dis Sci 2014;59:1235-1243.
28. Sugimoto M, Uotani T, Sahara S, et al. Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion. Helicobacter 2014;19:312-318.
29. Hsu PI, Chen WC, Tsay FW, et al. Ten-day quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy. Helicobacter 2014;19:74-79.
30. Liu KS, Hung IF, Seto WK, et al. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. Gut 2014;63:1410-1415.
31. Delchier JC, Malfertheiner P, Thieroff-Ekerdt R. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther 2014;40:171-177.
32. Gisbert JP, Perez-Aisa A, Rodrigo L, et al. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection. Dig Dis Sci 2014;59:383-389.
33. Fiorini G, Vakil N, Zullo A, et al. Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection. Clin Gastroenterol Hepatol 2013;11:507-510.
34. Shavakhi A, Tabesh E, Yaghoutkar A, et al. The effects of multistrain probiotic compound on bismuth-containing quadruple therapy for Helicobacter pylori infection: a randomized placebo-controlled triple-blind study. Helicobacter 2013;18:280-284.
35. Navarro-Rodriguez T, Silva FM, Barbuti RC, et al. Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study. BMC Gastroenterol 2013;13:56.
36. Emara MH, Mohamed SY, Abdel-Aziz HR. Lactobacillus reuteri in management of Helicobacter pylori infection in dyspeptic patients: a double-blind placebo-controlled randomized clinical trial. Therap Adv Gastroenterol 2014;7:4-13.
37. Passariello A, Agricole P, Malfertheiner P. A critical appraisal of probiotics (as drugs or food supplements) in gastrointestinal diseases. Curr Med Res Opin 2014;30:1055-1064.
38. Fock KM. Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther 2014;40:250-260.
39. Ford AC, Moayyedi P. Whom should we 'test and treat' for Helicobacter pylori? BMJ 2014;348:g3320.
40. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008;372:392-397.
41. Bae SE, Jung HY, Kang J, et al. Effect of Helicobacter pylori eradication on metachronous recurrence after endoscopic resection of gastric neoplasm. Am J Gastroenterol 2014;109:60-67.
42. Choi J, Kim SG, Yoon H, et al. Eradication of Helicobacter pylori after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma. Clin Gastroenterol Hepatol 2014;12:793-800.
43. Selgrad M, Bornschein J, Rokkas T, Malfertheiner P. Helicobacter pylori: gastric cancer and extragastric intestinal malignancies. Helicobacter 2012;17(Suppl 1):30-35.
44. Rokkas T, Sechopoulos P, Pistiolas D, et al. The relationship of Helicobacter pylori infection and colon neoplasia, on the basis of meta-analysis. Eur J Gastroenterol Hepatol 2013;25:1286-1294. A large study demonstrating H. pylori as a risk factor for colonic neoplasms.
45. Selgrad M, Bornschein J, Kandulski A, et al. Helicobacter pylori but not gastrin is associated with the development of colonic neoplasms. Int J Cancer 2014;135:1127-1131.
46. Sonnenberg A, Genta RM. Helicobacter pylori is a risk factor for colonic neoplasms. Am J Gastroenterol 2013;108:208-215.
47. Abbass K, Gul W, Beck G, et al. Association of Helicobacter pylori infection with the development of colorectal polyps and colorectal carcinoma. South Med J 2011;104:473-476.
48. Strofilas A, Lagoudianakis EE, Seretis C, et al. Association of Helicobacter pylori infection and colon cancer. J Clin Med Res 2012;4:172-176.
49. Robertson DJ, Sandler RS, Ahnen DJ, et al. Gastrin, Helicobacter pylori, and colorectal adenomas. Clin Gastroenterol Hepatol 2009;7:163-167.
50. Watson SA, Grabowska AM, El-Zaatari M, Takhar A. Gastrin: active participant or bystander in gastric carcinogenesis? Nat Rev Cancer 2006;6:936-946.
51. Drasar BS, Shiner M, McLeod GM. Studies on the intestinal flora. I. The bacterial flora of the gastrointestinal tract in healthy and achlorhydric persons. Gastroenterology 1969;56:71-79.
52. Irrazabal T, Belcheva A, Girardin SE, et al. The multifaceted role of the intestinal microbiota in colon cancer. Mol Cell 2014;54:309-320.
53. Yin YN, Wang CL, Liu XW, et al. Gastric and duodenum microflora analysis after long-term Helicobacter pylori infection in Mongolian Gerbils. Helicobacter 2011;16:389-397.
54. Hsu WY, Lin CH, Lin CC, et al. The relationship between Helicobacter pylori and cancer risk. Eur J Intern Med 2014;25:235-240.
55. Wang Y, Zhang FC, Wang YJ. Helicobacter pylori and pancreatic cancer risk: a meta-analysis based on 2049 cases and 2861 controls. Asian Pac J Cancer Prev 2014;15:4449-4454.